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Abstract
Background: Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with comorbidities and
multidrug therapy is complicated by mixed acid-base, hydro-electrolyte and lactate disorders. Aim of this study was to
determine the relationships of these disorders with the requirement for and duration of noninvasive ventilation (NIV) when
treating hypercapnic respiratory failure.
Methods: Sixty-seven consecutive patients who were hospitalized for hypercapnic COPD exacerbation had their clinical
condition, respiratory function, blood chemistry, arterial blood gases, blood lactate and volemic state assessed. Heart and
respiratory rates, pH, PaO2 and PaCO2 and blood lactate were checked at the 1st, 2nd, 6th and 24th hours after starting NIV.
Results: Nine patients were transferred to the intensive care unit. NIV was performed in 11/17 (64.7%) mixed respiratory
acidosis–metabolic alkalosis, 10/36 (27.8%) respiratory acidosis and 3/5 (60%) mixed respiratory-metabolic acidosis patients
(p=0.026), with durations of 45.169.8, 36.268.9 and 53.364.1 hours, respectively (p=0.016). The duration of ventilation
was associated with higher blood lactate (p,0.001), lower pH (p=0.016), lower serum sodium (p=0.014) and lower chloride
(p=0.038). Hyponatremia without hypervolemic hypochloremia occurred in 11 respiratory acidosis patients. Hypovolemic
hyponatremia with hypochloremia and hypokalemia occurred in 10 mixed respiratory acidosis–metabolic alkalosis patients,
and euvolemic hypochloremia occurred in the other 7 patients with this mixed acid-base disorder.
Conclusions: Mixed acid-base and lactate disorders during hypercapnic COPD exacerbations predict the need for and
longer duration of NIV. The combination of mixed acid-base disorders and hydro-electrolyte disturbances should be further
investigated.
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Introduction
Hypercapnic respiratory failure is a complex condition
associated with the malfunction of various organs and systems
crucial for many physiological processes, leading to an acid-base
imbalance.
Carbon dioxide (CO2) is not the only independent variable that
may cause alterations in acid-base status. Total serum protein,
albumin in particular, plays an important role, as does the strong
ion difference (SID), that is the difference between the strong
positive ions in the plasma (sodium (Na
+), potassium (K
+), calcium
(Ca
2+), and magnesium (Mg
2+)) and the strong negative ions
(chloride (Cl
2) and lactate (Lac
2)):
SID~ NazzKzzCa2zzMg2z 
{ Cl
{zLac{ ½  : ð1Þ
At pH 7.4, 37uC and a partial carbon dioxide tension of
40 mmHg, the ideal value of SID is 42 mmol/L . An increased
SID causes alkalosis; a reduced SID causes acidosis. Altering SID
means altering the water dissociation equilibrium. This provides
more/less H
+ for electroneutrality, with a change in [H
+], and so a
change in pH.
Acid-base and electrolyte balance are part of the same picture
because, for a given increase in CO2, the only way to minimize the
resulting acidemia is to produce compensatory metabolic alkalosis,
which is obtained through complex urinary ion excretion
mechanisms [2]. Thus, fluid homeostasis depends on the correct
relationship between lung and kidney activities because they
regulate most of the CO2 and hydrogen (H
+) concentrations in the
extracellular volume, whose total solutes consist almost entirely of
Na
+,C l
2 and bicarbonate ions (HCO
32).
In hypoxic and hypercapnic COPD patients, fluid homeostasis
is disturbed, with avid retention of sodium and water [3]. The
increase in sodium retention by the kidneys during COPD, and
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failure (cor pulmonale) and by other pathophysiological mecha-
nisms involving renal and hormonal abnormalities [3,4].
In hypercapnic COPD exacerbations, the sudden decrease in
ventilation causes an acute respiratory acidosis or deteriorates a
pre-existing chronic respiratory acidosis. Due to the high
prevalence of comorbidities [5] and the associated multidrug
therapies in these patients, mixed acid-base and hydro-electrolyte
disorders are becoming increasingly common, particularly in the
critically ill and elderly populations.
This study had the following aims: to evaluate mixed acid-base,
hydro-electrolyte and lactate disorders in patients with hypercap-
nic COPD exacerbation; to determine the relationship among
these disorders, a poor response to pharmacological treatment and
the requirement for noninvasive ventilation (NIV); and to analyze
the link between these disorders and the duration of NIV in the
treatment of hypercapnic respiratory failure.
Methods
Ethics Statement
The institutional review board for human studies (Fondazione
Eleonora Lorillard Spencer Cenci Ethics Committee) for human
studies approved the protocol, and written consent was obtained
from the subjects or their surrogates.
Study design
We investigated patients consecutively hospitalized in our
respiratory ward (Respiratory Diseases Unit, Policlinico Umberto
I, Rome) for COPD exacerbation and hypercapnic respiratory
failure. Between January and April 2010, sixty-seven patients were
consecutively hospitalized for COPD exacerbation and hypercap-
nic respiratory failure. COPD and COPD exacerbation were
defined according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [6]. Hypercapnia was defined by
a PaCO2$45 mmHg on arterial blood gas (ABG) analysis [6].
Patients were excluded from this descriptive study if they had
concomitant pneumonia, acute lung injury (ALI) or acute
respiratory distress syndrome (ARDS), and contraindications to
noninvasive ventilation (NIV) [7]. Patients enrolled were not
necessarily at the first COPD exacerbation treated with NIV, but
those being on chronic NIV treatment at home were excluded.
Comorbidities were identified on the basis of clinical records,
concomitant therapy, and/or investigations carried out at hospital
admission.
Baseline demographic characteristics and clinical parameters,
routine blood chemistry and ABG were assessed at admission.
The level of consciousness was assessed using the Glasgow
Coma Scale [8]. The severity of the clinical condition was
quantified by the Acute Physiology and Chronic Health
Evaluation II score [9].
Patients were classified into pure respiratory acidosis or mixed
defect (mixed respiratory acidosis–metabolic alkalosis and mixed
respiratory-metabolic acidosis) categories [10]. Hypernatremia
and hyponatremia were classified as hypovolemic, euvolemic and
hypervolemic [11,12], according to the clinical assessment, total
body water (TBW), relative body water deficit, serum urea to
creatinine ratio, serum sodium (sNa
+), urinary sodium (uNa
+),
plasma osmolality (Posm) and urine specific gravity (SG). TBW
was expressed as a percentage of body weight (body weight *
correction factor, where the correction factor was 0.6 for men, 0.5
for women and elderly men and 0.45 for elderly women). Body
water deficit was calculated using the following equation:
TBW ðÞ   1{ 140=Naz ðÞ ½  :
Plasma osmolality was calculated using the following equation:
2N a z ½  z
Glucose ½ 
18
z
BUN ½ 
2:8
:
Because the patients’ clinical conditions did not allow us to
conduct reliable pulmonary function tests, the data (FVC and
FEV1) considered for the analysis were those measured subse-
quently at a stable clinical condition (or rather when vital and gas-
exchange parameters improved and stabilized and patients’
dyspnea was not severe enough to not allow respiratory manouvres
required by lung function testing).
Initially, all patients received controlled oxygen therapy with a
Venturi mask, in order to maintain an arterial oxygen saturation
(SaO2) at least $90%, and conventional treatments, including
nebulized bronchodilators, intravenous corticosteroids, antibiotics
(if necessary) and other drugs, depending on the concomitant
comorbidities. NIV was initiated when controlled oxygen therapy
and convientional medical treatments failed to improve the clinical
conditions, or rather when respiratory distress with accessory
muscle use or abdominal paradox and tachypnea (respiratory rate
.24/min) were associated with persistent arterial impairment
(pH,7.35, PaCO2.45 mmHg, and PaO2/FiO2,200) despite
optimal pharmacological treatment and oxygen therapy [7,13].
NIV was performed via an oronasal mask using a pressure support
turbine ventilator (Polar 2 Hackermann & Bild Ltd., Crespellano,
Bologna, Italy) with a bi-tube connection. The pressure support,
PEEP and flow-by trigger values were adjusted to obtain a tidal
volume of 6–8 ml/kg and to gain the best oxygenation and reduce
the respiratory rate. They were modified based on the blood gas
data. Heart and respiratory rates, pH, PaO2 and PaCO2 and
blood lactate were checked on the 1
st,2
nd,6
th and 24
th hours after
starting NIV.
NIV was withdrawn when the clinical condition improved and
stabilized, as defined by the following objective parameters:
respiratory rate ,24/min, heart rate ,110/min, pH.7.35 and
SaO2.90% on FiO2,40% [14]. Patients were a priori considered
for invasive mechanical ventilation if the following conditions were
present: a worsening of arterial pH and carbon dioxide tension
despite correct NIV administration, an onset of coma, cardiovas-
cular instability or poor compliance with the NIV device [15].
Statistical analysis
All quantitative variables are summarized as mean and standard
deviation (SD), and the qualitative variables are summarized as
frequency and percentage. The results are reported separately for
each of the two groups (NIV use and no NIV use). The statistical
analysis was conducted by parametric or non-parametric test,
according to the distribution of variables as assessed by the
Shapiro-Wilk test. Student’s t-test for unpaired data was used to
compare the quantitative variables between the two groups (NIV
use and no NIV use), while the chi-squared test was used for
qualitative variables. The unadjusted odds ratio (OR) for NIV use
vs. no NIV use and its associated 95% confidence interval (95%
CI) were calculated for each variable by a logistic regression
analysis. One-way ANOVA for repeated measures was used with
the clinical parameters, ABG results and lactate values to evaluate
the effects of NIV use over 24 h. Contrast analysis, a priori
specified, was used for comparisons versus previous time points.
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identified according to the ABG analysis values (respiratory
acidosis, mixed respiratory acidosis–metabolic alkalosis and mixed
respiratory-metabolic acidosis) were evaluated using the Kruskal-
Wallis H test. The Mann-Whitney U test with Bonferroni
correction was applied to evaluate the differences of various
parameters at each time point between respiratory acidosis
patients and mixed respiratory acidosis–metabolic alkalosis
patients. Linear regression analysis was applied to evaluate the
relationships between NIV duration and various parameters.
Statistical analysis was performed using SPSS Advanced
Statistical 10.0 software (SPSS Inc., Chicago, Illinois, USA).
Results
Between January and April 2010, 75 patients were consecutively
hospitalized for COPD exacerbation and hypercapnic respiratory
failure, but 67 were enrolled in the study population (5 patients
were excluded for being on chronic NIV treatment at home and
the other 3 for the presence of concomitant pneumonia).
We considered 58 of the 67 patients initially enrolled, as 9 were
excluded because they were transferred to the intensive care unit
for pH,7.1, hypercapnic coma or hemodynamic instability
(Figure 1).
The enrolled COPD patients had multiple comorbidities, such
as hypertension (27 patients, 46.5%); ischemic heart disease (11,
18.9%); degenerative, hypertensive and valvular heart disease (25
patients, 43.1%); atrial fibrillation and other arrhythmias (18,
31%); cor pulmonale (13, 22.4%); peripheral artery disease (9,
15.5%); diabetes mellitus (17, 29.3%); chronic renal failure (20,
34.5%); and obstructive sleep apnea syndrome (4, 6.9%).
Therefore they were on multidrugs treatments including diuretics,
ACE inhibitors, angiotensin receptor antagonists, digoxin, anti-
arrhythmic drugs (such as propafenone, amiodarone, selective
beta-blockers and verapamil), oral hypoglycemic agents, insulin,
allopurinol, aspirin, statins and inhaled bronchodilators.
NIV was initiated in 24 patients and succeeded in correcting
respiratory acidosis in all of them. The mean duration of NIV was
42.4610.5 hours, and the mean IPAP employed was
1664 cmH2O. Supplementary oxygen was administered during
ventilation, which was continuous until clinical conditions were
stable with pauses for administration of conventional medications,
feeding and general care. None of the patients required the
interruption of the ventilatory assistance for discomfort, or refused
the treatment. The only complications recorded were 1 case of
Figure 1. Flow chart of the consecutive COPD patients with acute hypercapnic exhacerbation enrolled in the study.
doi:10.1371/journal.pone.0035245.g001
Mixed Acid-Base Disorders in Respiratory Failure
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35245nasal cutaneous sores and 2 cases of gastric distension, neither of
which required interrupting the ventilatory assistance.
Patient demographics and clinical characteristics are shown in
table 1. Clinical and metabolic parameters, ABG analysis,
electrolyte values, lactate, and urinalysis with electrolytes are
shown in table 2.
Compared to patients undergoing standard therapy, subjects
requiring NIV had a higher respiratory rate; lower PaO2, PaO2/
FiO2, alveolar–arterial PaO2 gradient, Na
+,C l
2, pH and serum
lactate; and higher PaCO2 and blood lactate (Table 2, figure 2).
The changes in clinical parameters, ABG results and lactate
values during the first 24 hours of ventilation are shown in table 3.
Using the ABG data and assessing the SID, we identified 36
patients with pure respiratory acidosis (anion gap
11.462.3 mmol/L; SID 40.761.2 mmol/L), 17 patients with
mixed respiratory acidosis–metabolic alkalosis (anion gap
9.661.5 mmol/L; SID 49.162.0 mmol/L) and other 5 with
mixed respiratory-metabolic acidosis (anion gap 25.963.6 mmol/
L; SID 29.261.8 mmol/L) (Figure 3).
Patients with mixed respiratory acidosis–metabolic alkalosis
were more likely to use NIV than those with the pure respiratory
acidosis, and their NIV duration was longer (Table 4). NIV was
used for 3 of the patients with mixed respiratory-metabolic
acidosis, and these patients had the longest ventilation times
(Table 4).
NIV duration was significantly associated with higher blood
lactate, lower pH and lower serum Na
+ and Cl
2 concentrations, as
shown by their regression coefficients (b=17.038 and p,0.001 for
lactate, b=2111.975 and p=0.016 for pH, b=20.478 and
p=0.014 for Na
+, and b=20.660 and p=0.038 for Cl
2).
In respiratory acidosis and mixed respiratory acidosis–metabolic
alkalosis NIV patients, heart rate, respiratory rate, pH, PaO2,
PaCO2 and blood lactate improved in the first 6 hours of NIV
(Figure 4), while significant improvements in the same parameters
were observed between the 6
th and the 24
th hour of ventilation in
the mixed respiratory-metabolic acidosis patients (data not shown).
We also evaluated hydro-electrolyte balance and identified 11
respiratory acidosis patients who had normochloremic hypervol-
emic hyponatremia due to chronic renal failure (n=2), cirrhosis
(n=1), hypothyroidism (n=1), or chronic congestive heart failure
(n=7).
Of the patients with mixed respiratory acidosis–metabolic
alkalosis, 10 had hypovolemic hyponatremia, hypochloremia and
hypokalemia due to thiazide or loop diuretic use associated with
diarrhea and vomiting during a gastroenteritis episode (n=2),
profuse sweating from febrile influenza syndrome (n=4) or
(probably) poor dietary fluid intake (n=4). Euvolemic hypochlor-
emia due to thiazide or loop diuretic use not associated with
extrarenal hydro-electrolyte loss was detected in 7 patients with
mixed respiratory acidosis–metabolic alkalosis.
In mixed respiratory-metabolic acidosis patients, the metabolic
acidosis was due to an exacerbation of chronic renal failure (n=1),
rhabdomyolysis (n=1), ketoacidosis in decompensated insulin-
dependent diabetes mellitus (n=2) or metformin-related lactic
acidosis (n=1 obese diabetic patient).
Discussion
Hypercapnic respiratory failure during acute COPD exacerba-
tion is an alarming event that requires careful management of the
resulting respiratory acidosis. The final outcome depends on
various factors, such as the patient’s overall health status and
concomitant comorbidities, the baseline lung function, and the
disease severity as judged by the need for assisted ventilation and
the degree of acidosis [16]. Our observations provide evidence that
mixed acid-base and lactate disorders in patients with hypercapnic
respiratory failure due to COPD exacerbation lead to the need for
and longer duration of NIV. More data should be provided to
evaluate this association with combined mixed acid-base and
hydroelectrolyte disorders.
Mixed respiratory acidosis–metabolic alkalosis
We observed that metabolic alkalosis with hyponatremia and/
or hypochloremia aggravated the respiratory acidosis due to the
COPD exacerbation. Mixed respiratory acidosis–metabolic alka-
losis patients were more likely to use NIV and were subjected to
longer periods of ventilation compared to those with pure
respiratory acidosis. The requirement for and duration of NIV
was associated with low serum sodium and chloride, common
findings in diuretic-induced metabolic alkalosis. The clinical
parameters and ABG analysis indicated more severe ventilatory
impairment in the patients with mixed respiratory acidosis–
metabolic alkalosis than in those with pure respiratory acidosis,
Table 1. Patients demographics and clinical characteristics.
Variables Total (n=58) NIV use (n=24) No NIV use (n=34) p-value
a
Gender: Male (n, %) 43 (74.2) 18 (75) 25 (73.5) 0.028
b
Gender: Female (n, %) 15 (25.8) 6 (25) 9 (26.5)
Age (years) 79.365.1 79.865.4 78.864.9 0.511
BMI (Kg/m
2) 27.062.6 27.363.3 26.762.1 0.356
SBP (mmHg) 138.8616.9 135.8617.7 140.9616.2 0.256
DBP (mmHg) 76.768.2 74.669.8 78.266.7 0.097
FEV1 (L) 2.360.7 2.460.8 2.360.7 0.773
FEV1 (%) 57.969.9 58.669.6 57.4610.2 0.654
GCS 12.461.6 11.861.8 12.861.3 0.022
APACHE II score 17.766.2 18.467.5 17.265.1 0.477
Data expressed as Mean 6 Standard Deviation.
aStudent t-test for unpaired data;
bChi-Squared Test. NIV=non invasive ventilation; BMI=Body Mass Index; SBP=Systolic Blood Pressure; DBP=Diastolic Blood Pressure; FEV1=Forced Expiratory Volume;
GCS=Glasgow Coma Scale; APACHE II score=Acute physiology and chronic health evaluation II score.
doi:10.1371/journal.pone.0035245.t001
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Variables Total (n=58) NIV use (n=24) No NIV use (n=34) p-value
a
Glycemia (mg/dl) 139.5680.5 150.3691.2 131.9672.4 0.396
Serum albumin (g/L) 3.960.5 4.060.5 3.960.4 0.339
Serum uric acid (mg/dl) 5.762.1 5.962.5 5.661.9 0.651
Serum creatinine (mg/dl) 1.360.7 1.460.7 1.360.6 0.798
Heart rate (beats/minute) 116.7611.7 119.7612.4 114.6610.9 0.108
Respiratory rate (breaths/minute) 29.764.0 32.263.0 27.963.6 ,0.001
PaO2 (mmHg) 59.766.7 54.564.6 63.465.4 ,0.001
PaO2/FiO2 178.6638.5 160.5638.2 191.5633.6 0.002
P(A-a)O2 20.266.1 18.265.6 21.666.1 0.037
pH 7.3160.06 7.2260.04 7.3460.04 ,0.001
PaCO2 (mmHg) 68.668.3 75.665.5 63.766.2 ,0.001
Lactate (mmol/L) 1.760.2 3.160.6 0.760.2 ,0.001
Serum HCO3
2 (mmol/L) 33.667.8 35.6610.5 32.165.0 0.089
sNa
+ (mmol/L) 133.469.8 129.4610.9 136.268.0 0.008
sK
+ (mmol/L) 4.060.7 3.960.9 4.060.5 0.683
sCl
2 (mmol/L) 98.166.1 95.066.8 100.264.5 0.001
sCa
2+ (mmol/L) 1.2160.2 1.1960.1 1.2360.1 0.645
sMg
2+ (mmol/L) 160.3 160.2 0.960.3 0.592
Plasma osmolality (Posm) 304.9617.9 309.7621.4 301.4614.5 0.084
uNa
+ (mmol/L) 141.5687.2 123.1682.2 154.5689.4 0.178
uK
+ (mmol/L) 90.3628.6 101.3632.0 85.2630.0 0.055
uCl
2 (mmol/L) 168.2662.5 176.8669.8 162.1657.0 0.384
Urine specific gravity 1025.769.1 1025.669.1 1025.769.2 0.980
Data expressed as Mean 6 Standard Deviation.
aStudent t-test for unpaired data. ABG=arterial blood gases; NIV=non invasive ventilation; FiO2=Fraction of inspired O2; P(A-a)O2=alveolar-arterial PO2 gradient;
sNa
+=serum sodium; sK
+=serum potassium; sCl
2=serum chloride; sCa
2+=serum calcium; sMg
2+=serum magnesium; uNa
+=urine sodium; uK
+=urine potassium;
uCl
2=urine chloride.
doi:10.1371/journal.pone.0035245.t002
Figure 2. Unadjusted odds ratios (OR) and 95% confidence intervals for NIV use with respect to clinical parameters, ABG results
and lactate and electrolyte values that were statistically significant. NIV=noninvasive ventilation; ABG=arterial blood gases;
RR=respiratory rate; P(A-a)O2=alveolar–arterial PO2 gradient; sNa
+=serum sodium; sCl
2=serum chloride.
doi:10.1371/journal.pone.0035245.g002
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simultaneous alkalinizing processes.
In patients with hypercapnic respiratory failure due to COPD
exacerbation, the presence of a sufficient metabolic compensation
and adequate renal function significantly decreases mortality [17].
In our study, the bicarbonate increase overcame the expected
renal compensatory response, reflecting a mixed acid-base
disorder with metabolic alkalosis due to various causes in patients
with multiple comorbidities and undergoing multidrug treatment.
The use of diuretics for cardiovascular comorbidities was the main
cause of metabolic alkalosis with hyponatremia and/or hypo-
chloremia.
Metabolic alkalosis causes a direct depression of the respiratory
drive, leads to diminished chemoreceptor stimulation and
consequently reduces alveolar ventilation to increase PaCO2 and
lower pH toward normal levels [18,19,20].
Metabolic alkalosis is usually associated with hypochloremia,
which has a relevant inhibitory effect on the ventilatory response
to hypercapnia. A reduction of serum chloride is associated with a
reduced chloride concentration in the cerebrospinal fluid [21].
Because the cerebrospinal fluid does not contain significant weak
acids, a reduction of its chloride level will result in a bicarbonate
increase to maintain electroneutrality, which raises the central pH
and leads to hypoventilation.
In addition, metabolic alkalosis has been associated with
increased airway resistance [22]. In our study, it probably
contributed to the increased respiratory impairment in the mixed
respiratory acidosis–metabolic alkalosis patients when compared
to the subjects with pure respiratory acidosis.
In a study investigating the effects of metabolic acid-base
changes on central ventilatory chemoregulation in normocapnic
and hypercapnic COPD patients, the ventilatory responsiveness to
carbon dioxide was not significantly altered by the induced
metabolic state [23]. These results may seem inconsistent with our
observations, but we believe that they are not comparable for
several reasons. In the van de Ven et al. study [23], chronic
metabolic acidosis and alkalosis were experimentally induced by
the oral administration of acetazolamide and furosemide,
respectively, and were not caused by various comorbidities from
their multidrug treatments. The authors evaluated the responses of
inspired ventilation (VI) and mouth occlusion pressure (P0.1)t o
changes in PaCO2, while we investigated the possible deleterious
effects of metabolic alkalosis on the ventilatory response to
hypercapnia by assessing the requirement and duration of NIV
in a real clinical scenario.
Table 3. Clinical parameters, ABG analysis and lactate values at different time during NIV.
Variables 1 h 2 h 6 h 24 h p-value
a
Heart rate (beats/min) 113.4614.7 111.3614.8
** 106.9616.8
** 100.3617.8
** ,0.001
Respiratory rate (breaths/
min)
29.664.9 28.564.7
** 26.065.0
** 22.664.4
** ,0.001
pH 7.2660.07 7.3860.07
** 7.3160.07
** 7.3560.06
** ,0.001
PaO2 (mmHg) 59.368.9 61.869.3
* 64.3610.0
** 66.5610.1
* ,0.001
PaCO2 (mmHg) 68.0612.2 66.5612.2
* 62.7612.5
** 59.5611.7
** ,0.001
Lactate (mmol/L) 2.960.6 2.660.7
** 2.160.8
** 1.460.8
** ,0.001
Data expressed as Mean 6 Standard Deviation.
aANOVA test for repeated measures;
**p,0.001;
*p,0.01 contrast analysis vs previous time point. ABG=arterial blood gases; NIV=non invasive ventilation.
doi:10.1371/journal.pone.0035245.t003
Figure 3. Acid-base balances in patients with hypercapnic COPD exacerbation. Black lozenge: Respiratory acidosis. White square: Mixed
respiratory acidosis–metabolic alkalosis; Black triangle: Mixed respiratory-metabolic acidosis.
doi:10.1371/journal.pone.0035245.g003
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Patients Overall NIV use (n, %)
a Hours of NIV (Mean ± SD)
b
Overall 58 24, 41.4 42.4610.5
Respiratory acidosis 36 10, 27.8 36.268.9
Mixed respiratory acidosis – metabolic
alkalosis
17 11, 64.7 45.169.8
Mixed respiratory - metabolic acidosis 5 3, 60.0 53.364.1
NIV=non invasive ventilation; ABG=arterial blood gases.
ap=0.026, Chi-Squared test vs no NIV use.
bp=0.016, Kruskal-Wallis H test.
doi:10.1371/journal.pone.0035245.t004
Figure 4. Trends over time in heart rate (panel A), respiratory rate (panel B), pH (panel C), PaO2 (panel D), PaCO2 (panel E) and
blood lactate (panel F) during NIV. *p ,0.0125, Mann-Whitney U test between groups with Bonferroni correction. NIV=noninvasive ventilation.
doi:10.1371/journal.pone.0035245.g004
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COPD patients was first reported in a study that showed an
improvement in gas exchange and clinical symptoms after
correcting the coexistent metabolic alkalosis [24].
Discontinuing furosemide, which is prescribed for peripheral
edema in patients with stable COPD, increases the minute
ventilation and lowers the PaCO2 by correcting metabolic alkalosis
[25]. Hypoventilation in response to metabolic alkalosis has serious
implications in patients with high PaCO2 and low PaO2. COPD
patients with a tendency toward hypercapnia require extra
attention because hypercapnia is believed to be an ominous sign
for morbidity and mortality [26,27]. The increased PaCO2 caused
by furosemide may lead to fluid retention, which may counteract
the diuretic effects of furosemide. This is of clinical relevance,
especially considering that loop diuretics are prescribed to a
substantial number of COPD patients. Thus, other types of
diuretics should be considered when diuretic therapy is indicated
in hypercapnic COPD patients. Spironolactone, which causes no
acid/base shifts, or acetazolamide, which causes a metabolic
acidosis, may be better options. Because loop diuretics are often
necessary in COPD patients with cor pulmonale or cardiac
comorbidities, acetazolamide could be added to counteract the
metabolic alkalosis [28].
Lactate disorders
Lactate clearance, as a surrogate for the magnitude and
duration of global tissue hypoxia, is used for diagnostic,
therapeutic and prognostic purposes. The normal reference values
for lactate are traditionally considered 160.5 mmol/l in normal
patients and ,2 mmol/l in critically ill patients [29].
Increased lactate production indicates increased anaerobic
metabolism associated with tissue hypoxia; lactate is one of the
intermediate products that increase as a consequence of
metabolism derangement during hypoxia [29].
Lactate clearance is a useful prognostic indicator. It reveals
improvements in systemic tissue hypoxia and is associated with a
decreased mortality rate. Patients with greater early lactate
clearance after 6 hours of intensive care treatment have better
outcomes than do subjects with lower lactate clearance [30].
In addition, early lactate clearance is significantly associated
with decreased levels of inflammatory biomarkers, improvements
in organ dysfunction and improved outcomes in severe sepsis and
septic shock [31]. In addition, persistently elevated lactate is
associated with a higher mortality rate [32,33].
In patients with respiratory failure, the early lactate clearance
could be useful to assess the metabolic response to therapy and to
identify individuals who are able to reverse the metabolic
derangement. Lactate clearance deserves the same diagnostic
relevance as other noninvasive markers of delivery/consumption/
demand mismatches. While tissue pH, O2 saturation and PCO2
can offer a precise ‘‘local’’ picture of cellular oxygen disturbance,
lactate does not. Nevertheless, systematically checking lactate
clearance could be used to tailor the therapy in many cases of
respiratory insufficiency [34,35].
The greatest amounts of lactate are produced by the skin,
erythrocytes, skeletal muscles, and leukocytes [36]. Blood lactate
concentration may only qualitatively reflect the metabolic
phenomena occurring in the tissues. Moreover, lactate production
is actually a consequence (and not the cause) of cellular acidosis.
Because increased lactate production coincides with acidosis,
lactate measurement is an excellent ‘‘indirect’’ marker of the
metabolic condition of a cell.
We considered blood lactate as a diagnostic marker of tissue
hypoxia and respiratory muscle fatigue (lactate is a valuable energy
source within the working muscle), an indirect indicator of
hypercapnic COPD exacerbation severity and, as a consequence,
an indirect indicator of its response to treatment.
In our study, lactate improved over time once NIV was started.
Patients with higher blood lactate were more likely to require NIV
and needed longer ventilation times. The effects of hyperlactate-
mia on pH were attenuated in patients with concomitant
hypochloremic metabolic alkalosis. Therefore, acid-base analysis
should not only be based on traditional parameters, such as pH,
HCO3
2 and the anion gap, but should rely on a more
comprehensive evaluation [37]. According to Stewart [1], lactate
production modifies the SID and thus influences one of the
determinants of H
+ concentration. While there are tissues whose
deranged metabolic pathways need lactate as an intermediate
metabolite to survive, the production of lactate itself depends on
pH [37]. Moreover, the pH controls the rate of lactate uptake
from blood by hypoxic skeletal muscles [38].
Mixed respiratory-metabolic acidosis
In this study we identified a few patients with mixed respiratory-
metabolic acidosis who required long NIV periods. Metabolic
acidosis stimulates hyperventilation, but these patients had
impaired ventilation, probably as a result of muscle wasting due
to the metabolic academia [39]. Hospitalized patients with acute
COPD exacerbations associated with mixed respiratory-metabolic
acidosis represent more severe cases with a higher mortality rate
than those with the respiratory component of acidemia alone [40].
Preliminary results and further research
In this descriptive study, we did not analyze the subgroups
derived from the combinations of mixed acid-base disorders and
hydro-electrolyte disturbances because the number of patients was
not sufficient to guarantee a significant statistical power for this
purpose
Probably the descriptive design of the study does not allow us to
obtain definitive conclusions, but we strongly believe to have
investigate a field not yet explored, eventually stimulating further
prospective multicentric studies in order to completely clarify this
topic, which recurs frequently in clinical practice.
Our preliminary results suggest, in fact, that in the clinical
respiratory care researchers should address the following ques-
tions: a) whether lactate clearance is useful during acute
respiratory failure to identify patients at high risk of negative
outcomes and, potentially, to increase the intensity of the
therapeutic approach; b) whether lactate clearance is predictive
of positive outcome and could confirm to physicians that the
current therapeutic approach is appropriate; and c) how both the
metabolic components of mixed acid-base disorders and the
hydroelectrolyte balance alterations may worsen the hypercapnic
respiratory failure caused by the COPD exacerbation and may
affect its resolution through standard medical therapy, either alone
or combined with NIV.
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